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Autosomal dominant North Carolina macular dystrophy (NCMD) is believed to represent a failure 
of macular development. The disorder has been linked to two loci, MCDR1 (chromosome 6q16) and 
MCDR3 (chromosome 5p15-p13). Recently, non-coding variants upstream of PRDM13 (MCDR1) 
and a duplication including IRX1 (MCDR3) have been identified. However, the underlying disease-
causing mechanism remains uncertain. Through a combination of sequencing studies on eighteen 
NCMD families, we report two novel overlapping duplications at the MCDR3 locus, in a gene desert 
downstream of IRX1 and upstream of ADAMTS16. One duplication of 43 kb was identified in nine 
families (with evidence for a shared ancestral haplotype), and another one of 45 kb was found in a single 
family. Three families carry the previously reported V2 variant (MCDR1), while five remain unsolved. The 
MCDR3 locus is thus refined to a shared region of 39 kb that contains DNAse hypersensitive sites active 
at a restricted time window during retinal development. Publicly available data confirmed expression 
of IRX1 and ADAMTS16 in human fetal retina, with IRX1 preferentially expressed in fetal macula. 
These findings represent a major advance in our understanding of the molecular genetics of NCMD and 
provide insights into the genetic pathways involved in human macular development.
North Carolina macular dystrophy (NCMD) is a rare autosomal dominant disorder in which there is abnormal 
development of the macula, a crucial structure of the central retina responsible for central vision and colour 
perception1. Understanding the genetics of rare developmental macular conditions is key for unravelling the 
mechanism of development of this structure that is found only in higher primates within mammals1. NCMD 
shows fully penetrant inheritance and is considered a non-progressive disorder with a wide range of phenotypic 
manifestations, usually affecting both eyes symmetrically2, 3. Phenotypic presentation varies from mild cases with 
drusen-like deposits covering the macular region but with little or no visual impairment, to severe cases with 
marked central chorioretinal atrophy and poor vision. Although generally non-progressive, complications asso-
ciated with choroidal neovascularization can contribute to visual deterioration.
The molecular genetics of NCMD has been extensively investigated with the disorder being mapped to chro-
mosome 6q16 (MCDR1, MIM:136550) in multiple families of different ethnic origins since the early 1990s4–10. A 
similar phenotype has been assigned to a second locus at 5p15-p13 (MCDR3, MIM:608850)3, 11. Interestingly, sev-
eral studies reported evidence for ancestral haplotypes at the MCDR1 locus2, 12, 13. Early sequencing studies of the 
two disease intervals failed to identify exonic disease-causing variants2, 14. More recently, three novel single nucle-
otide variants (SNVs) were identified in 11 families at the MCDR1 locus, within a DNase1 hypersensitivity site 
(DHS), in the non-coding interval between PRDM13 and the neighbouring overlapping genes CCNC/TSTD315. 
Two tandem duplications including the full coding region of PRDM13, with some additional upstream and 
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downstream sequence included, were also identified15, 16. One MCDR3-linked family of Danish origin3 was 
found to carry a 900 kb tandem duplication15 that includes the entire coding sequence of IRX1. However, dupli-
cations of IRX1 have been observed in several normal individuals from the Database of Genome Variants15, 17  
and the significance of this reported variant is uncertain. Thus, the causative mechanism at the 5p15-p13 NCMD 
locus remains unclear.
In this report we present a combination of genomic investigations in a cohort of 18 NCMD families. The aim 
of this study was to identify any causative molecular changes and mechanism of disease in these families.
Results
Families and brief clinical phenotype description. Eighteen families with phenotypes consistent with 
a diagnosis of NCMD were included in the study (Table 1 and Supplementary Fig. S1). Four families were previ-
ously reported: suggestive linkage at the MCDR3 locus has been recently described for family 114, family 2 was 
originally reported to be linked to the MCDR3 locus11, and families 12 and 13 were linked to MCDR17, 9, with 
family 13 recently found to carry the SNV V2 upstream of PRDM1315. All families (mostly of small size) showed 
autosomal dominant inheritance and had at least one individual with Grade 3 disease. DNA samples from a total 
of 56 affected and 33 unaffected family members were available for genetic analysis.
Figure 1 shows fundus autofluorescence and optical coherence tomography (OCT) images for selected indi-
viduals from families 2 and 3. Individual IV:5 from family 2 presents with a well demarcated, relatively symmet-
rical, bilateral area of macular chorioretinal atrophy, while individual IV:3 from family 3 shows a mild form of 
disease with relatively symmetrical, bilateral hyperfluorescent drusen-like deposits concentrated in the macular 
region.
Haplotype sharing analysis can exclude or suggest genetic mapping at known NCMD loci. 
Haplotype sharing analysis was carried out using the Homozygosity Haplotype (HH) method18 to search for 
shared identical-by-descent (IBD) chromosomal segments among affected individuals within each family. This 
analysis was performed in those families for which Illumina single-nucleotide polymorphism (SNP) array data 
were available for more than one affected family member (families 1–5 and 12–13). The 6q16 MCDR1 locus was 
excluded in four families, including the two previously MCDR3-linked families 114 and 211 and unreported fami-
lies 3 and 4 (Supplementary Figs S2–S5). Family 5 showed evidence for haplotype sharing at many regions across 
the genome, including both the 6q16 and 5p15-p13 loci (Supplementary Fig. S6). The two previously reported 
MCDR1-linked families 127 and 139 were confirmed with evidence for a Region with a Conserved HH (RCHH) 
at the 6q16 locus, and not at the 5p15-p13 locus (Supplementary Figs S7–S8).
Family 
number Family ID Origin Phenotype
Experimental 
procedure
Causative allele 
change Nucleotide change
Number of 
affected family 
members analysed
Number of 
unaffected family 
members analysed
Total number of 
family members 
analysed
1 GC1980614 Latvian NCMD SNP, aCGH, WGS, PCR/Sanger chr5:4391377–4436535 45158 bp duplication 5 1 6
2 GC1562611 British NCMD SNP, aCGH, WGS, PCR/Sanger chr5:4396927–4440442 43515 bp duplication 9 8 17
3 GC15119 British NCMD SNP, aCGH, WGS, PCR/Sanger chr5:4396927–4440442 43515 bp duplication 4 0 4
4 GC13840 British NCMD SNP, WGS, PCR/Sanger chr5:4396927–4440442 43515 bp duplication 3 0 3
5 GC19075 British NCMD SNP, WGS, PCR/Sanger chr5:4396927–4440442 43515 bp duplication 3 0 3
6 GC15475 British NCMD SNP, WGS, PCR/Sanger chr5:4396927–4440442 43515 bp duplication 1 0 1
7 GC11709 British NCMD SNP, WGS, PCR/Sanger chr5:4396927–4440442 43515 bp duplication 1 0 1
8 GC16913 British NCMD PCR/Sanger chr5:4396927–4440442 43515 bp duplication 1 0 1
9 GC4092 British NCMD PCR/Sanger chr5:4396927–4440442 43515 bp duplication 1 0 1
10 GC23501 British NCMD PCR/Sanger chr5:4396927–4440442 43515 bp duplication 2 1 3
11 GC15416 British NCMD SNP, PCR/Sanger chr6:100040987 G > C (V2) 2 0 2
12 GC37227 British NCMD SNP, PCR/Sanger chr6:100040987 G > C (V2) 12 8 20
13 GC172259, 15 French NCMD SNP, PCR/Sanger chr6:100040987 G > C (V2) 12 15 27
Total 56 33 89
Table 1. Summary of families with two newly reported tandem duplications at the MCDR3 locus and 
previously identified V2 variant at the MCDR1 locus. Genomic coordinates refer to GRCh37/hg19 assembly. 
SNP, aCGH, WGS, PCR/Sanger indicate Illumina SNP array, array-based comparative genomic hybridization, 
whole-genome sequencing and Sanger Sequencing, respectively. Five affected members from five additional 
NCMD families were also tested for the presence of previously reported SNVs V1-V315 and the two tandem 
duplications found in this study, but none of these affected individuals was found to carry any of the variants.
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Two additional NCMD families shown to carry previously reported SNV upstream of PRDM13 at 
the MCDR1 locus. All families, except families 1–4 for which linkage at the 6q16 locus had been excluded via 
haplotype sharing analysis, were tested with Sanger Sequencing for the three previously reported SNVs (V1-V3) 
upstream of PRDM1315. In addition to the previously reported V2 family 1315, two more NCMD families were 
found to harbour the variant V2 (family 11 and the previously described MCDR1-linked family 127).
Array-based comparative genomic hybridization (aCGH) uncovers duplications at the MCDR3 
locus in three NCMD families. To investigate the MCDR3 locus for the presence of structural variants 
(SVs), an aCGH experiment using 10,000 probes spanning the region at chr5:11882–10140073 (GRCh37/hg19) 
was performed in three affected individuals from families 1–3 which did not show linkage at the 6q16 locus 
(Supplementary Figs S2–S4). All three families were found to harbour heterozygous duplications of approximately 
45 kb, downstream of IRX1 and upstream of ADAMTS16 (Fig. 2a). The duplications were found to be located in 
the minimal overlapping regions chr5:4391880–4434888 (GRCh37/hg19) in family 1 and chr5:4397221–4440150 
(GRCh37/hg19) in families 2 and 3. These SVs were not seen in 16 control individuals included in the same 
aCGH experiment, nor were they present in whole genome sequencing (WGS) data from 650 individuals with 
inherited retinal disease19 or in publicly available population copy number variant (CNV) data (CNV browser)20.
WGS identifies four more NCMD families with duplications at the MCDR3 locus. Thirteen 
affected individuals from families 1–7 underwent WGS. Graphical visualisation of individual paired-end reads 
using Integrative Genomics Viewer (IGV)21, 22 confirmed the presence of heterozygous tandem duplications in 
families 1–3 (Fig. 2b). Precise breakpoint coordinates were identified from coverage changes, split reads and 
Figure 1. NCMD typical clinical presentation in two selected individuals from family 3 (IV:3) and family 2 
(IV:5). Each panel shows fundus autofluorescence and optical coherence tomography (OCT) images. Individual 
IV:3 (a,b) from family 3 shows a mild form of disease with relatively symmetrical, bilateral hyperfluorescent 
drusen-like deposits concentrated within the macular region and an otherwise normal OCT. Individual IV:5 
(c,d) from family 2 presents with a well demarcated, relatively symmetrical and bilateral area of macular 
chorioretinal atrophy.
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chimeric reads. Family 1 had a 45158 bp duplicated region (GRCh37/hg19 chr5:4391377–4436535) and families 
2 and 3 shared an identical 43515 bp tandem duplication (GRCh37/hg19 chr5:4396927–4440442), overlapping 
the first identified SV by 85% of the sequence (GRCh37/hg19 chr5:4396925–4436534). Subsequently, members 
from families 4–7 were also found to carry the same 43 kb duplication.
Polymerase chain reaction (PCR) primers were designed to amplify the novel sequence across the break-
point between duplicated copies (Table 2, Fig. 3) and used to confirm the predicted breakpoints and assess seg-
regation of the two variants in all available affected and unaffected members of families 1 and 2 (Fig. 3, Table 1 
and Supplementary Fig. S1). PCR was then used to genotype the available affected individuals from fami-
lies 3–7 and confirmed the presence of a band in all affected individuals tested (Table 1 and Supplementary 
Fig. S1).
Genotyping reveals three additional previously unmapped NCMD families with duplications 
at the MCDR3 locus. The remaining 8 unmapped families were tested with the established PCR assay for 
both duplications, and 3 of them (families 8–10) were also found to carry the 43 kb duplication (Table 1 and 
Figure 2. NCMD is caused by intergenic duplication events located between IRX1 and ADAMTS16. (a) aCGH 
experiment (10,000 probes spanning the MCDR3 locus at GRCh37/hg19 chr5:11882-10140073, panel I) 
performed in three affected individuals from families 1–3 that were found to harbour heterozygous duplications 
of approximately 43 kb (panel II) located in a gene desert downstream of IRX1 and upstream of ADAMTS16 
(panel III), also confirmed by WGS (b) by changes in coverage from concordant and discordant reads (panel 
I and II, respectively) and identification of chimeric reads, pair-reads with opposing orientation (displayed 
in green, panel III). Panels are presented with a split view option within IGV. The duplications are located in 
the overlapping regions GRCh37/hg19 chr5:4391880–4434888 (family 1) and GRCh37/hg19 chr5:4397221–
4440150 (families 2 and 3).
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Supplementary Fig. S1). Thus, a total of 9 not knowingly related families were shown to harbour the same 43 kb 
tandem duplication at the MCDR3 locus. Five affected members available from the remaining 5 families did not 
carry either of the two novel duplications.
Duplication size Primer sequence Tm (°C) Length (bp)
43 kb
F 5′-TTGTGGACTGAGCAAGCAAG-3′
63 532
R 5′-GGAGCAGAAGTTAAATGTGGAGA-3′
45 kb
F 5′-TTTGCTTGATCAATTCTGCTG-3′
63 500
R 5′-TTCTCAGTTGGAAGAGCACAAA-3′
Table 2. Primer sequences used for the segregation analysis of the two novel MCDR3 duplications identified in 
the study. Tm = Temperature of melting.
Figure 3. PCR and Sanger sequencing validation of duplication breakpoints and segregation in family 1 (a) 
and family 2 (b). All available individuals (Supplementary Fig. S1) were tested with primers designed across the 
predicted breakpoints to generate a unique junction fragment sequence. The exact breakpoint is marked with a 
red bar; PCR primers are represented with blue arrows. L = ladder; W = water; “-” = genomic DNA pooled from 
control individuals.
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Haplotype sharing analysis suggests presence of ancestral haplotypes at the MCDR1 and 
MCDR3 loci. We hypothesized that finding the same 6q16 SNV and 5p15 duplication with identical break-
point in 3 and 9 families respectively, could be due to two different shared ancestral haplotypes suggestive of a 
common founder, in keeping with previous reports on other 6q16 NCMD families5, 12, 13, 15. Therefore, haplotype 
sharing analysis was performed using available Illumina SNP array data from 14 affected individuals in 3 families 
carrying the 6q16 V2 variant (families 11–13) and 14 affected individuals in 6 families carrying the 5p15 43 kb 
duplication (families 2–7). Using a cut-off of 2.0 cM and 2.5 cM respectively, the results confirmed that all the 
genotyped 6q16 individuals collectively shared a RCHH of approximately 2.5 Mb from GRCh37/hg19 coordi-
nate chr6:98962591 (rs150396) to chr6:101468591 (rs1321204) at the MCDR1 locus, and all the genotyped 5p15 
individuals collectively shared a RCHH of approximately 0.9 Mb from GRCh37/hg19 coordinate chr5:4327455 
(rs155354) to chr5:5210050 (rs1560063) at the MCDR3 locus (Supplementary Tables S1–S2 and Supplementary 
Figs S9–S10).
Discussion
We report two distinct heterozygous tandem duplications at the MCDR3 locus in 30 affected individuals from 
10 NCMD families. The two novel SVs overlap the previously described duplication found in a single NCMD 
family of Danish origin15 and further refine the 5p15 NCMD locus to a shared region of 39 kb in a gene desert 
downstream of IRX1 and upstream of ADAMTS16 (800 kb and 693.9 kb from the respective transcription start 
sites, Fig. 4).
We postulated that the 39 kb shared region could harbour cis-acting elements that contribute to the fine tuning 
of gene expression during macular development, affecting target gene expression spatially, temporally and/or 
quantitatively. Publicly available platforms were queried for informative data on gene expression and chroma-
tin accessibility in relevant tissue types. A dataset screening for gene expression in fetal retina confirmed high 
expression of IRX1 at 19–20 weeks of gestation in the macula, and medium expression levels in other regions 
(Supplementary Fig. S11). In contrast, ADAMTS16 had medium expression levels throughout the retina23, 24. 
Although no role in retinal pathophysiology has been described for ADAMTS16, the gene has high sequence 
similarity to ADAMTS18 which has been previously associated with retinal disease25. Overall, the data suggest 
that the pattern and/or refined spatial dosage and timing of expression of the transcription factor IRX1 may be 
important in macular development. A second dataset provided information on open chromatin conformation 
using DNase-accessible sequencing in fetal retina tissues at 5 stages from gestation day 72 to 125 (~10 to 18 
weeks)26. Different sites were identified to be open/active within the 39 kb shared region at four out of five time 
points (~10–15 weeks of gestation) available during retinal development (Table 3). Interestingly, one of the sites 
was active during three developmental stages and the remaining four sites were functionally active as two over-
lapping pairs. At the last time point (day 125, ~18 weeks), all sites were inactive/closed. In the context of human 
macular development, the sites are active during the period where retinal progenitor cells are proliferating and 
differentiating towards photoreceptor fate27; by week 14 of gestation, cells of the central retina exit mitosis27, cor-
responding to the period where DHSs are turning off.
As mentioned, the MCDR1 locus on chromosome 6q16 is associated with variants sited within a DHS, which 
suggests that aspects of macular development may be highly gene dosage sensitive. Exploring the function and 
precise target of such regulatory domains in both loci will be essential for understanding the disease mecha-
nism of NCMD and investigating its potential role in the context of normal macular development. The graded 
Figure 4. Schematic representation of the MCDR3 locus which is refined to a 39 kb shared genomic region 
(GRCh37/hg19 chr5:4396925–4436534). The shared sequence between a previously reported duplication and 
the two novel SVs identified in this study is located in a large gene desert, downstream of IRX1 and upstream 
of ADAMTS16, 800 kb and 693.9 kb from their respective transcription start sites. Publicly available NGS 
datasets were queried for informative data on chromatin accessibility and 3 sites were found active from human 
gestation day 72 to 105 in fetal retina, suggestive of functional acting elements within this site.
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expression of IRX1 and known involvement in retinal development28, 29, but not ADAMTS16 in the macular 
region, suggests that IRX1 is the probable target of the putative retinal regulatory element which, when dupli-
cated, may cause misregulation of IRX1.
Eye development, like other organogenesis processes, requires the precise spatio-temporal and quantitative 
expression of genes, orchestrated by a complex network of regulatory mechanisms influencing critical transcrip-
tion factors and other developmental genes. The lack of readily accessible animal or in vitro models has hindered 
detailed understanding of macular development, as this structure only evolved in higher primates among mam-
mals. Recently, disrupted developmental expression of the transcription factor and histone methyltransferase 
PRDM1330, 31 was suggested as a disease mechanism for NCMD at the 6q16 locus, based on the identification 
of non-coding SNVs and duplication events residing in an overlapping region upstream of PRDM13 in many 
MCDR1 families. Differential regulation of PRDM13 in eyecups derived from wild-type induced pluripotent stem 
cells (iPSCs)15, 16 was suggested. However, no causal relationship between the non-coding variants and PRDM13 
expression has been identified.
Despite variable presentation in affected individuals, the NCMD phenotypic spectrum is indistinguishable 
in patients assigned to either of the two linked loci, MCDR1 and MCDR3. Whether a biological and functional 
connection between PRDM13 at the MCDR1 locus and the most likely candidate gene IRX1 at the MCDR3 locus 
exists warrants further investigation. iPSC technology and CRISPR manipulation in eye cups from normal and 
affected individuals may help elucidate the molecular mechanism32, 33 and the potential molecular links between 
the two genes. Importantly, the involvement of ancestral variation at both the 6q16 and 5p15 loci (Supplementary 
Tables S1–S2 and Supplementary Figs S9–S10) in such a highly penetrant dominant disease is intriguing, with 
the implication that there may exist a significant number of unrecognized related NCMD families. Full clinical 
examination reveals a high degree of penetrance, but visually unaffected individuals in whole families may fail to 
be ascertained.
Finally, the two novel duplications identified in this study significantly further the understanding of the 
molecular genetics of NCMD at the MCDR3 locus and provide additional effective tools for the molecular diag-
nosis of NCMD families.
Materials and Methods
Families. All families were ascertained at Moorfields Eye Hospital, London, United Kingdom, expect for fam-
ily 114 (Vision Centre, Children’s Clinical University Hospital, Riga, Latvia) and family 139 (Centre Hospitalier 
Régional Universitaire de Lille, France). When possible, retinal imaging was undertaken using colour fundus 
photography, fundus autofluorescence and OCT imaging. Blood/saliva samples were collected for DNA extrac-
tion, genotyping and sequence analyses. The study protocol was approved by the local ethics committees (Central 
Medical Ethics Commitee of Latvian Republic; NRES Committee London – Camden & Islington) and conformed 
to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants, or their 
parents, before inclusion in the study.
Genotyping. Genomic DNA was extracted from whole blood/saliva and genotyped using the Illumina 
HumanOmniExpress-24 v1.0 beadchip (Illumina, Inc., San Diego, CA, USA). Genotypes were determined using 
the Genotyping Module in the Illumina GenomeStudio v2011.1 software.
Haplotype sharing analysis. In order to search for chromosomal segments sharing the same haplotype 
across affected individuals (within the same family or across different families), the non-parametric HH method18 
was used for the analysis of those affected individuals that were genotyped with the Illumina array. The HH is 
a type of haplotype described by the homozygous SNPs only (all heterozygous SNPs are removed) and, there-
fore, can be uniquely determined on each chromosome. Since affected family members who inherited the same 
mutation from a common ancestor share a chromosomal segment IBD around the disease gene, they should not 
have discordant homozygous calls in the IBD region and thus they should share the same HH. The HH approach 
predicts IBD regions through the identification of RCHHs defined as those regions with a shared HH among 
affected individuals and a genetic length longer than a certain cut-off value (recommended cut-off for Illumina 
HumanOmniExpress array is 2.5/3.0 cM for the analysis of one single family).
aCGH. aCGH was performed at Oxford Gene Technology (OGT) (Begbroke, United Kingdom) using a cus-
tom design consisting of 10,000 probes spanning the MCDR3 locus at GRCh37/hg19 chr5:11882–10140073 
(approximately 1 probe every 1,000 bp), designed with Agilent e-Array software (Agilent Technologies Inc., 
Santa Clara, CA, USA), in three individuals from families 1–3 (Supplementary Fig. S1). Sixteen other individuals 
Chromosome
Start 
position
End 
position
Gestation day 
(fetal retina)
5 4418340 4418490 74
5 4420820 4420970 74, 89, 103
5 4418320 4418470 85
5 4420860 4421010 85
5 4409260 4409410 103
Table 3. DHSs active during fetal retina development at the 39 kb shared duplicated region (GRCh37/hg19 
chr5:4396925–4436534). Gestation day 125 shows no active site at the 39 kb shared region. The fetal retina 
datasets were available from ENCODE26, produced by the Stamatoyannopoulos’ laboratory.
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affected by non-ocular phenotypes were also included in the experiment and used as controls in the analysis. 
Scanned images of the arrays were processed with OGT CytoSure™ Interpret Software v4.4 using the Accelerate 
Workflow for calling CNVs. Duplications or deletions were considered when the log2 ratio of the Cy3/Cy5 inten-
sities of a region encompassing at least four probes was > 0.3 or < −0.6, respectively (software default settings).
WGS and bioinformatics analysis. WGS was performed using the Illumina HiSeq X10 platform 
(Illumina, Inc., San Diego, CA, USA), generating minimum coverage of 30X. Reads were aligned to the hg19 
human reference sequence (build GRCh37) with novoalign (version 3.02.08). The aligned reads were sorted by 
base pair position and duplicates were marked using novosort. Discordant reads were marked with samblaster 
(version 0.1.20) and sent to a separate file for manual inspection of breakpoints using the IGV (version 2.3.61). 
SVs were manually investigated using the IGV by identifying peaks of discordant reads which were interpreted as 
breakpoints. The identified duplicated regions were also screened for the presence of common copy number var-
iants using data from the CNV browser20 (https://personal.broadinstitute.org/handsake/mcnv_data/) and WGS 
data from 650 individuals with inherited retinal disease19.
Sanger sequencing validation of duplication events. Segregation analysis of the duplication events 
identified by WGS was performed using primers (Table 2) designed to span the end of first copy and start of 
second copy. A graphical representation is shown in Fig. 3. After sequence confirmation with Sanger sequencing, 
PCR was used to genotype selected individuals from all identified families.
In silico analysis of duplicated sequences and expression of flanking genes. The Encyclopedia of 
DNA Elements (ENCODE)26 was interrogated for fetal retina datasets of interest. Bed files from DNA-seq data-
sets (ENCFF249FGP, ENCFF937NUZ, ENCFF401BCF, ENCFF591NRB, ENCFF265ZNN, Stamatoyannopoulos’ 
laboratory) were downloaded and investigated at the shared duplicated region with R Studio. A second microar-
ray expression dataset on human fetal retina (19–20 gestation week) was queried for the genes of interest24 using 
the platform GENEVESTIGATOR23.
Data availability statement. The datasets generated during the current study are not publicly available 
due to limitations imposed by the scope of participant consent, but are available from the corresponding authors 
on reasonable request.
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